XML 32 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Combinations
 9 Months Ended
Sep. 30, 2014
Business Combinations [Abstract]  
Business Combinations
Business Combinations

On July 17, 2014 the Company entered into a definitive license and supply agreement with MonoSol Rx, LLC (MonoSol) for the U.S. commercial rights to Zuplenz® (ondansetron) Oral Soluble Film (Zuplenz), an FDA approved product. The transaction was accounted for as a business combination under the acquisition method of accounting based on Accounting Standards Codification 805, "Business Combinations." Accordingly, the assets acquired and liabilities assumed were recorded at fair value. As of the issuance date of the condensed consolidated financial statements for the quarter ended September 30, 2014, the Company had not finalized the valuation of the acquired assets and liabilities for the transaction.

The following table summarizes the purchase price consideration and allocation of purchase price:

 
 
Total Acquisition Date Fair Value
Purchase price consideration:
 
 
Cash and cash equivalents
 
$
3,056

Common stock
 
2,482

Liabilities assumed:
 
 
Contingent consideration
 
741

Credit memos for expiring channel inventory
 
1,384

Total consideration
 
$
7,663

 
 
 
Asset acquired:
 
 
Zuplenz rights
 
$
7,663

Goodwill
 
—

Fair value of assets acquired
 
$
7,663



The above contingent consideration represents a risk adjusted net present value relating to cash payments on achievement of certain milestones.